Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation

Journal of Virology

Volumn 70, Issue 10, 1996, Pages 6862-6869

  Demers, G William ^a,b   Espling, Erik ^a   Harry, Jo Beth ^a   Etscheid, Beth G ^a   Galloway, Denise A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL TRANSFORMATION; DNA DAMAGE; DNA SYNTHESIS INHIBITION; GROWTH DISORDER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WART VIRUS;

EID: 0029815035     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.10.6862-6869.1996     Document Type: Article

References (64)

1. cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRb binding activity. Mol. Biol. Cell 3:655-665.
2. Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner. 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77:799-800.
3. Banks, L. M., C. Edmonds, and K. H. Vousden. 1990. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 5:1383-1389.
4. Blanton, R. A., M. D. Coltrera, A. M. Gown, C. L. Halbert, and J. K. McDougall. 1912. Expression of the HPV16 E7 gene generates proliferation in stratified squamous cell cultures which is independent of endogenous p53 levels. Cell Growth Differ. 3:791-802.
5. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by P21 deficiency. Nature (London) 377:552-557.
6. Chellappan, S. P., S. W. Hiebert, M. Mudruj, J. M. Horowitz, and J. R. Nevins. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061.
7. Cheng, S., D. C. Schmidt-Grimminger, T. Murant, T. R. Broker, and L. T. Chow. 1995. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:2335-2349.
8. Cordon-Cardo, C., and V. M. Richon. 1994. Expression of the retinoblastoma protein is regulated in normal human tissues. Am. J. Pathol. 144:500-510.
9. Crook, T., J. A. Tidy, and K. H. Vousden. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556.
10. Datto, M. B., Y. Yu, and X.-F. Wang. 1995. Functional analysis of the transforming growth factor beta responsive elements in the WAFI/CIP1/p21 promoter. J. Biol. Chem. 270:28623-28628.
11. Davies, R., R. Hicks, T. Crook, J. Morris, and K. Vousden. 1993. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 67:2521-2528.
12. Davies, R., and K. H. Vousden. 1992. Functional analysis of human papillomavirus type 16 E7 by complementation with adenovirus E1A mutants. J. Gen. Virol. 73:2135-2139.
13. Demers, G. W., S. A. Foster, C. L. Halbert, and D. A. Galloway. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA 91:4382-4386.
14. Demers, G. W., C. L. Halbert, and D. A. Galloway. 1994 Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 198:169-174.
15. Deng, C. X., P. M. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking P21 (C/P1/WAF1) undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
16. Dyson, N., P. M. Howley, K. Munger, and E. Harlow. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937.
17. Edmonds, C., and K. H. Vousden. 1989. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 63:2650-2656.
18. Egan, C., T. N. Jelsma, J. A. Howe, S. T. Bayley, B. Ferguson, and P. E. Branton. 1988. Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol. Cell. Biol. 8:3955-3959.
19. Elledge, S. J., and J. W. Harper. 1994. CDK. inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6:847-852.
20. Firzlaff, J. M., C. N. L. Hsia, C. L. Halbert, S. A. Jenison, and D. A. Galloway. 1987. Polyclonal antibodies to human papillomavirus type 6b and type 16 bacterially derived fusion proteins. Cancer Cells 5:105-113.
21. Firzlaff, J. M., B. Luscher, and R. N. Eisenman. 1991. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc. Natl. Acad. Sci. USA 88:5187-5191.
22. Foster, S. A., G. W. Demers, B. G. Etscheid, and D. A. Galloway. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:5698-5705.
23. Gage, J. R., C. Meyers, and F. O. Wettstein. 1990. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64:723-730.
24. Garcia, R., M. Coltrerea, and A. M. Gown. 1989. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am. J. Pathol. 134:733-739.
25. Halbert, C. L., G. W. Demers, and D. A. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
26. Halbert, C. L., G. W. Deniers, and D. A. Galloway. 1992. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66:2125-2134.
27. Hannon, G. J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-beta-indueed cell cycle arrest. Nature (London) 371:257-261.
28. Hawley-Nelson, P., K. H. Vousden, N. L. Hubbert, D. R. Lowy, and J. T. Schiller. 1989. HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:3905-3910.
29. Heck, D. V., C. L. Yee, P. M. Howley, and K. Munger. 1992. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA 89:4442-4446.
30. Hickman, E. S., S. M. Picksley, and K. H. Vousden. 1994. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:2177-2181.
31. Huang, P. S., D. R. Patrick, G. Edwards, P. J. Goodhart, H. E. Huber, L. Miles, V. M. Garsky, A. Oliff, and D. C. Heimbrook. 1993. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol. Cell. Biol. 13:953-960.
32. Ikeda, M. A., and J. R. Nevins. 1993. Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol. Cell. Biol. 13:7029-7035.
33. Jewers, R. J., P. Hildebrandt, J. W. Ludlow, B. Kell, and D. J. McCance. 1992. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 66:1329-1335.
34. Kessis, T. D., R. J. Slebos, W. G. Nelson, M. B. Kastan, B. S. Plunkett, S. M. Han, A. T. Lorincz, L. Hedrick, and K. R. Cho. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988-3992.
35. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
36. Laiho, M., J. A. DeCaprio, J. W. Ludlow, D. M. Livingston. and J. Massague. 1990. Growth inhibition by TGF-b linked to suppression of retinoblastoma protein phosphorylation. Cell 62:175-185.
37. Martin, L., G. W. Demers, and D. A. Galloway. Unpublished data.
38. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques 7:980-990.
39. Missero, C., E. Calautti, R. Eckner, J. Chin, L. H. Tsai, D. M. Livingston, and G. P. Dotto. 1995. Involvement of the cell-cycle inhibitor Cipl/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA 92:5451-5455.
40. Missero, C., E. Filvaroff, and G. P. Dotto. 1991. Induction of transforming growth factor beta 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. Proc. Natl. Acad. Sci. USA 88:3489-3493.
41. Münger, K., W. C. Phelps, V. Bubb, P. M. Howley, and R. Schlegel. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
42. Munger, K., B. A. Werness, N. Dyson, W. C. Phelps, E. Harlow, and P. M. Howley. 1989. Complex formation of the human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:4099-4105.
43. Munger, K., C. L. Yee, W. C. Phelps, J. A. Pietenpol, H. L. Moses, and P. M. Howley. 1991. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65:3943-3948.
44. Nakagawa, S., S. Watanabe, H. Yoshikawa, Y. Taketani, K. Yoshiike, and T. Kanda. 1995. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212:535-542.
45. Ohtani, K., J. DeGregori, and J. R. Nevins. 1995. Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl. Acad. Sci. USA 92:12146-12150.
46. cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027.
47. Phelps, W. C., K. Munger, C. L. Yee, J. A. Barnes, and P. M. Howley. 1992. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 66:2418-2427.
48. Pietenpol, J. A., R. W. Stein, E. Moran, P. Yaciuk, R. Schlegel, R. M. Lyons, M. R. Pittelkow, K. Munger, P. M. Howley, and H. L. Moses. 1990. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61:777-785.
49. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22.
50. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
51. Schmitt, A., J. B. Harry, B. Rapp, F. O. Wettstein, and T. Iftner. 1994. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J. Virol. 68:7051-7059.
52. Schwarz, E., U. K. Freese, L. Gissmann, W. Mayer, B. Roggenbuck, A. Stremlau, and H. zur Hausen. 1985. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (London) 314: 111-114.
53. Schwarz, J. K., C. H. Bassing, I. Kovesdi, M. B. Datto, M. Blazing, S. George, X.-F. Wang, and J. R. Nevins. 1995. Expression of E2F1 transcription factor overcomes type b transforming growth factor-mediated growth suppression. Proc. Natl. Acad. Sci. USA 92:483-487.
54. Sedman, S. A., N. L. Hubbert, W. C. Vass, D. R. Lowy, and J. T. Schiller. 1992. Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J. Virol. 66:4201-4208.
55. Slebos, R. J., M. H. Lee, B. S. Plunkett, T. D. Kessis, B. O. Williams, T. Jacks, L. Hedrick, M. B. Kastan, and K. R. Cho. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 91:5320-5324.
56. Stirdivant. S. M., H. E. Huber, D. R. Patrick, D. Defeo-Jones, E. M. McAvoy, V. M. Garsky, A. Oliff, and D. C. Heimbrook. 1992. Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product. Mol. Cell. Biol. 12:1905-1914.
57. Storey, A., N. Almond, K. Osborn, and L. Crawford. 1990. Mutations of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J. Gen. Virol. 71:965-970.
58. Watanabe, S., T. Kanda, H. Sato, A. Furuno, and K. Yoshiike. 1990. Mutational analysis of human papillomavirus type 16 E7 functions. J. Virol. 64:207-214.
59. Watanabe, S., H. Sato, N. Komiyama, T. Kanda, and K. Yoshiike. 1992. The E7 functions of human papillomaviruses in rat 3Y1 cells. Virology 187:107-114.
60. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
61. Xiong, Y., D. Kuppuswamy, Y. Li, E. M. Livanos, M. Hixon, A. White, D. Beach, and T. D. Tlsty. 1996. Alteration of cell cycle complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation. J. Virol. 70:999-1008.
62. Zerfass, K., A. Schulze, D. Spitkovsky, V. Friedman, B. Henglein, and P. Jansen-Durr. 1995. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69:6389-6399.
63. Zbang, H., G. J. Hannon, and D. Beach. 1995. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.
64. zur Hausen, H. 1991. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13.